APO Research
Talk to an analyst

APO RESEARCH · REPORT

PMO (Phosphorodiamidate Morpholino Oligomers) Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis and Forecast 2026-2032

29 December 2025196 pages

Choose your research edition.

Industry ResearchPMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of PMO (Phosphorodiamidate Morpholino Oligomers) Drug include Avidity Biosciences, Dyne, Nippon Shinyaku, NS Pharma, Inc. and Sarepta Therapeutics, Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for PMO (Phosphorodiamidate Morpholino Oligomers) Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of PMO (Phosphorodiamidate Morpholino Oligomers) Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for PMO (Phosphorodiamidate Morpholino Oligomers) Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the PMO (Phosphorodiamidate Morpholino Oligomers) Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for PMO (Phosphorodiamidate Morpholino Oligomers) Drug revenue, projected growth trends, production technology, application and end-user industry.

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Company

Avidity Biosciences

Dyne

Nippon Shinyaku

NS Pharma, Inc.

Sarepta Therapeutics, Inc

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Type

DMD exon 45 Based

DMD exon 51 Based

DMD exon 53 Based

Other

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Application

Hospital

Clinic

PMO (Phosphorodiamidate Morpholino Oligomers) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PMO (Phosphorodiamidate Morpholino Oligomers) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PMO (Phosphorodiamidate Morpholino Oligomers) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PMO (Phosphorodiamidate Morpholino Oligomers) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of PMO (Phosphorodiamidate Morpholino Oligomers) Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of PMO (Phosphorodiamidate Morpholino Oligomers) Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PMO (Phosphorodiamidate Morpholino Oligomers) Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. DMD exon 45 Based Major Player Table 3. DMD exon 51 Based Major Player Table 4. DMD exon 53 Based Major Player Table 5. Other Major Player Table 6. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Clinic Major Player Table 9. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Trends Table 10. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Drivers Table 11. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Opportunities and Challenges Table 12. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Restraints Table 13. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Region (2021-2026) Table 16. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2027-2032) & (US$ Million) Table 17. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Region (2027-2032) Table 18. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Players (US$ Million) & (2021-2026) Table 19. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Players (2021-2026) Table 20. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Key Players Headquarters & Area Served Table 22. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players, Product Type & Application Table 23. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2026) & (US$ Million) Table 28. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2027-2032) & (US$ Million) Table 29. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Type (2021-2026) Table 30. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Type (2027-2032) Table 31. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2026) & (US$ Million) Table 33. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2027-2032) & (US$ Million) Table 34. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Application (2021-2026) Table 35. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Application (2027-2032) Table 36. Avidity Biosciences Company Information Table 37. Avidity Biosciences Business Overview Table 38. Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 40. Avidity Biosciences Recent Development Table 41. Dyne Company Information Table 42. Dyne Business Overview Table 43. Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 45. Dyne Recent Development Table 46. Nippon Shinyaku Company Information Table 47. Nippon Shinyaku Business Overview Table 48. Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 50. Nippon Shinyaku Recent Development Table 51. NS Pharma, Inc. Company Information Table 52. NS Pharma, Inc. Business Overview Table 53. NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 55. NS Pharma, Inc. Recent Development Table 56. Sarepta Therapeutics, Inc Company Information Table 57. Sarepta Therapeutics, Inc Business Overview Table 58. Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio Table 60. Sarepta Therapeutics, Inc Recent Development Table 61. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2026) & (US$ Million) Table 62. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2027-2032) & (US$ Million) Table 63. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2026) & (US$ Million) Table 64. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2027-2032) & (US$ Million) Table 65. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 66. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021-2026) & (US$ Million) Table 67. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (US$ Million) & (2027-2032) Table 68. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2026) & (US$ Million) Table 69. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2027-2032) & (US$ Million) Table 70. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2026) & (US$ Million) Table 71. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2027-2032) & (US$ Million) Table 72. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 73. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021-2026) & (US$ Million) Table 74. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (US$ Million) & (2027-2032) Table 75. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2026) & (US$ Million) Table 76. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2027-2032) & (US$ Million) Table 77. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2026) & (US$ Million) Table 78. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2027-2032) & (US$ Million) Table 79. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2026) & (US$ Million) Table 80. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2027-2032) & (US$ Million) Table 81. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2026) & (US$ Million) Table 82. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2027-2032) & (US$ Million) Table 83. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 84. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Region (US$ Million) & (2021-2026) Table 85. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Region (US$ Million) & (2027-2032) Table 86. SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2026) & (US$ Million) Table 87. SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2027-2032) & (US$ Million) Table 88. SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2026) & (US$ Million) Table 89. SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2027-2032) & (US$ Million) Table 90. SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021-2026) & (US$ Million) Table 92. SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (US$ Million) & (2027-2032) Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Image Figure 2. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. DMD exon 45 Based Image Figure 5. DMD exon 51 Based Image Figure 6. DMD exon 53 Based Image Figure 7. Other Image Figure 8. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size (US$ Million) & (2021-2032) Figure 13. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Type (2021-2032) Figure 20. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Application (2021-2032) Figure 23. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Type (2021-2032) Figure 25. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Application (2021-2032) Figure 26. North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Country (2021-2032) Figure 27. United States PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Type (2021-2032) Figure 32. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Application (2021-2032) Figure 33. Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Country (2021-2032) Figure 34. Germany PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Type (2021-2032) Figure 44. China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Application (2021-2032) Figure 45. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Type (2021-2032) Figure 47. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Application (2021-2032) Figure 48. Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Region (2021-2032) Figure 49. Japan PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Type (2021-2032) Figure 57. SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Application (2021-2032) Figure 58. SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Country (2021-2032) Figure 59. Brazil PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • DMD exon 45 Based
  • DMD exon 51 Based
  • DMD exon 53 Based
  • Other
Applications
  • Hospital
  • Clinic
Companies covered
  • Avidity Biosciences
  • Dyne
  • Nippon Shinyaku
  • NS Pharma, Inc.
  • Sarepta Therapeutics, Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Type
  3. 1.2.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 DMD exon 45 Based
  5. 1.2.3 DMD exon 51 Based
  6. 1.2.4 DMD exon 53 Based
  7. 1.2.5 Other
  8. 1.3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market by Application
  9. 1.3.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Dynamics
  1. 2.1 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Trends
  2. 2.2 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Drivers
  3. 2.3 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Opportunities and Challenges
  4. 2.4 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Perspective (2021-2032)
  2. 3.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Growth Trends by Region
  3. 3.2.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Players
  2. 4.1.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Key Players Headquarters & Area Served
  7. 4.4 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players, Product Type & Application
  8. 4.5 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market CR5 and HHI
  11. 4.6.3 2025 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Tier 1, Tier 2, and Tier 3
5 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Type
  1. 5.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2032)
  3. 5.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Type (2021-2032)
6 PMO (Phosphorodiamidate Morpholino Oligomers) Drug Market Size by Application
  1. 6.1 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2032)
  3. 6.3 Global PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Avidity Biosciences
  2. 7.1.1 Avidity Biosciences Company Information
  3. 7.1.2 Avidity Biosciences Business Overview
  4. 7.1.3 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Avidity Biosciences PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  6. 7.1.5 Avidity Biosciences Recent Developments
  7. 7.2 Dyne
  8. 7.2.1 Dyne Company Information
  9. 7.2.2 Dyne Business Overview
  10. 7.2.3 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Dyne PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  12. 7.2.5 Dyne Recent Developments
  13. 7.3 Nippon Shinyaku
  14. 7.3.1 Nippon Shinyaku Company Information
  15. 7.3.2 Nippon Shinyaku Business Overview
  16. 7.3.3 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Nippon Shinyaku PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  18. 7.3.5 Nippon Shinyaku Recent Developments
  19. 7.4 NS Pharma, Inc.
  20. 7.4.1 NS Pharma, Inc. Company Information
  21. 7.4.2 NS Pharma, Inc. Business Overview
  22. 7.4.3 NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 NS Pharma, Inc. PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  24. 7.4.5 NS Pharma, Inc. Recent Developments
  25. 7.5 Sarepta Therapeutics, Inc
  26. 7.5.1 Sarepta Therapeutics, Inc Company Information
  27. 7.5.2 Sarepta Therapeutics, Inc Business Overview
  28. 7.5.3 Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sarepta Therapeutics, Inc PMO (Phosphorodiamidate Morpholino Oligomers) Drug Product Portfolio
  30. 7.5.5 Sarepta Therapeutics, Inc Recent Developments
8 North America
  1. 8.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (2021-2032)
  2. 8.2 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2027-2032)
  5. 8.3 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2027-2032)
  9. 8.5 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country
  11. 8.6.1 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (2021-2032)
  2. 9.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2027-2032)
  5. 9.3 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2027-2032)
  9. 9.5 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country
  11. 9.6.1 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (2021-2032)
  2. 10.2 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2032)
  3. 10.2.1 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2026)
  4. 10.2.2 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2027-2032)
  5. 10.3 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Type (2021-2032)
  6. 10.4 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2032)
  7. 10.4.1 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2026)
  8. 10.4.2 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2027-2032)
  9. 10.5 China PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (2021-2032)
  2. 11.2 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2027-2032)
  5. 11.3 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2027-2032)
  9. 11.5 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country
  11. 11.6.1 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue (2021-2032)
  2. 12.2 SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country
  11. 12.6.1 SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA PMO (Phosphorodiamidate Morpholino Oligomers) Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst